Exhibit 1185 ยท Journal article (advocacy review)
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs
The authorization of user fees in 1992 has turned drug companies into the FDA's prime clients, deepening the regulatory and cultural capture of the agency.
Argues that the 1992 user-fee authorization made drug companies the FDA's prime clients and deepened regulatory and cultural capture, and recommends full public funding. Abstract read (OpenAlex). Normative argument built on selected studies.
- Source
- Light, Lexchin and Darrow, Journal of Law, Medicine and Ethics 41(3):590-600
- Date
- Fall 2013
- Quoted from
- Abstract
- Grade
- Peer-reviewed
- Document
- https://doi.org/10.1111/jlme.12068
- Accessed
- 2026-11-10
- Cited by
- Findings citing this exhibit
- Note
- Standing note: CONTESTED, keep in private notes. Advocacy review with causal wording the cited empirical studies do not support (see Carpenter 2003, Lietzan 2024). Do not cite on the page; use it only to show where the capture-side argument is made.